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INTRODUCTION
Metastatic breast cancer (MBC) is generally considered an 
incurable malignancy that shortens the survival of breast can-
cer patients. Palliative treatment, which is of limited clinical 
benefit, remains the most common treatment for MBC in 
spite of the recent advances in the management of this disease. 
Therefore, the median survival is only 24 to 30 months after 
the diagnosis of metastasis [1,2].
Various prognostic factors have been identified in patients 
with MBC. A hormone receptor (HR)-negative primary tu-
mor, high histological grade, large tumor size, positive lymph 
nodes, and old age are all associated with a poor survival out-
come, whereas metastases to the bones and soft tissue (as op-
posed to other sites) are associated with longer survival [1-6]. 
The actual survival rate of individual patients differs exten-
sively owing to the heterogeneity associated with MBC, and 
its prognosis and clinical course may be dependent on host 
factors [2,4]. While recent molecular studies aiming for im-
proved treatment outcome contributed towards the under-
standing of tumor heterogeneity and the genomic characteris-
tics of MBC [7,8], this knowledge is not integrated into daily 
practice and confers only limited survival benefits. In contrast, 
intrinsic subtypes have been identified by genomic studies, 
which resulted in therapies tailored to each subtype such as 
endocrine therapy and human epidermal growth factor recep-
tor 2 (HER2)-targeting therapies in MBC [9].
The metastasis-free interval (MFI) is easy to determine in 
clinical practice and therefore eliminates the requirement for 
sophisticated or expensive methods. It was previously report-
ed that MFI is associated with survival after metastasis, and 
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Purpose: We investigated the relationships between metastasis-
free interval (MFI) and tumor characteristics, and assessed the 
prognostic value of MFI for survival after metastasis in patients 
with metastatic breast cancer. Furthermore, we compared MFI 
among the subtypes. Methods: We identified 335 patients with 
postoperative tumor recurrence at distant site(s). All patients under-
went curative resection and had a MFI of at least 6 months. MFI 
was categorized as short (<2 years), intermediate (≥2 years and 
<5 years), or long (≥5 years). Overall survival after metastasis 
(OSM) was estimated. Results: Patients with a shorter MFI were 
younger, more likely to have initial metastasis to visceral organs, 
and had a larger tumor with a higher stage and grade as well as 
a higher rate of nodal involvement at initial diagnosis. Among 
136 patients with known disease subtypes, shorter MFI was as-
sociated with the triple-negative subtype while longer MFI was 
associated with the hormone receptor-positive/human epidermal 
growth factor receptor 2 negative subtype. Mortality after metas-
tasis declined sharply with increasing MFI up to approximately 2 
years, and continued gradually declining between 2 and 5 years. 
An MFI longer than 5 years did not add any survival benefit. MFI 
was a significant prognostic factor for OSM independent of nod-
al status, stage, metastatic site, and hormone receptor status of 
the metastasized cancer. Conclusion: MFI is closely related to bi-
ological characteristics of both primary tumors and their metas-
tases, and has a prognostic value for survival after metastasis. 
We therefore suggest investigation into treatments targeting im-
provement of MFI as a potential novel strategy.
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patients with a long MFI have a favorable prognosis even after 
metastasis [4,5]. In addition, MFI was reported to be associat-
ed with specific tumor characteristics including estrogen re-
ceptor (ER) status, suggesting that early recurrence is more 
prevalent in ER-negative cancer while late recurrence is com-
mon for ER-positive cancer [10-12]. However, studies investi-
gating the MFI associated with different MBC subtypes are 
limited in number. 
The objectives of this study were to investigate the relation-
ships between MFI and tumor characteristics, and to assess 
the prognostic value of MFI for survival after metastasis in 
MBC patients. Furthermore, we compared MFI among the 
subtypes.
METHODS
Patient selection
Between April 1989 and May 2008, 2,353 women consecu-
tively underwent surgery for breast cancer. The main patient 
characteristics, administered treatments, and associated out-
comes were documented in the hospital database. Of these 
2,353 patients, 438 patients had MBC. Patients with distant 
metastases at initial assessment (n= 72) were excluded. The 
patients with MFI shorter than 6 months were also excluded 
because they were considered to have metastatic disease at 
initial diagnosis (n= 31). Among the remaining 335 patients 
identified to have developed distant metastasis after the pri-
mary operation, the disease subtypes for 136 of the patients 
were determined based on the results of immunohistochem-
istry analysis. 
Immunohistochemistry
Formalin-fixed, paraffin-embedded tissue sections obtained 
from surgical specimens were stained with appropriate anti-
bodies to ER (1:100 clone 6F11; Novocastra, Newcastle upon 
Tyne, UK), progesterone receptor (PR) (clone 16; Novocastra), 
HER2 (4B5 monoclonal antibody; Ventana Medical Systems, 
Tucson, USA), and Ki-67 (MIB-1; Dako, Glostrup, Denmark). 
The HER2 status was determined through membranous 
staining using a scoring of 0, 1+, 2+, or 3+ based on the 
strength of membrane staining [12]. The HER2 status was 
considered positive if the score was 3+, and as negative, if the 
score was 0 or 1+. Tumors with a score of 2+ were sent for flu-
orescence in situ hybridization using the PathVysion HER2 
DNA Probe Kit (Abbott-Vysis, Des Plaines, USA). In order to 
establish the HER2 status in more of the patients, HER2 ex-
pression was evaluated using tissues from the primary tumor 
or the metastatic site. Ki-67 expression was determined in 92 
samples as the percentage of positive tumor cells, and strati-
fied as high or low using a cutoff of 14%. 
Patients (n= 136) were classified into HR-positive/HER2-
negative, HR-positive/HER2-positive, HR-negative/HER2-
positive, and HR-negative/HER2-negative (i.e., triple-negative 
[TN]) subtypes based on their tumor expression levels of ER, 
PR, and HER2.  
The staging was performed according to the guidelines of 
American Joint Committee on Cancer (AJCC), seventh edi-
tion. The modified Scarff-Bloom-Richardson grading system 
was used for tumor grading. Adjuvant systemic therapy and/
or radiotherapy were administered according to the standard 
guidelines based on patient age, primary tumor characteris-
tics, and axillary lymph node status. Endocrine therapy was 
administered to patients with HR-positive tumors. A 6-month 
follow-up scheme was advised and if the appointment was 
missed, the patient was contacted and asked to make a new 
appointment in order to minimize the risk of failure due to 
lack of follow-up and to improve the accuracy of survival data. 
The final update to the clinical database was made in December 
2013. Distant metastasis was defined as the recurrence of 
invasive cancer at distant organs excluding local recurrence 
(ipsilateral breast or chest wall) and regional recurrence (ipsi-
lateral axillary, infraclavicular, internal mammary, or supra-
clavicular) and was confirmed using imaging studies and/or 
tissue biopsies.
The Institutional Review Board (IRB) of Gangnam Severance 
Hospital approved the study in accordance with Good Clinical 
Practice guidelines and the Declaration of Helsinki (3-2014-
0048). The IRB granted a waiver for written documentation 
of informed consent from all participants because of the 
retrospective nature of the study design.
Definitions of MFI and MFI categorization
The MFI was defined as the interval between surgery and 
the date of diagnosis of the first distant relapse, which was 
longer than 6 months in each case. The MFI was then catego-
rized as short ( < 2 years), intermediate ( ≥ 2 years and < 5 
years), or long (≥ 5 years).
Statistical analysis
Our primary objective was to investigate the relationships 
between MFI and tumor characteristics. These relationships 
were compared using a chi-square test. One-way analysis of 
variation (ANOVA) was performed for comparison of MFIs 
among tumor subtypes. Our secondary objective was to de-
termine the overall survival after metastasis (OSM), which 
was calculated from the date of the first distant metastasis to 
the date of the last follow-up, or until death during the follow-
up period. The Kaplan-Meier method was used to estimate 
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OSM, and Cox hazards regression model was used for multi-
variate survival analysis. In order to investigate the relation-
ship between MFI and the risk of death associated with MBC, 
restricted cubic spline models, which are smoothly joined 
piecewise third order polynomials, were used [13]. These 
polynomials were fitted within intervals delimited by knots, 
and restrictions were placed on the resulting curve to ensure a 
smooth appearance at the knot points. A 3-knot analysis was 
performed. Using Harrell C-statistic, the concordance index 
(c-index) for time-to-event data was calculated, for which in-
creasing values between 0.5 and 1.0 indicates an increase in 
the accuracy of the prediction [14]. These analyses were per-
formed using SPSS version 18 (SPSS Inc., Chicago, USA) and 
R (http://www.r-projet.org) software. Statistical significance 
was determined by a p-value < 0.05 or a 95% confidence in-
terval (CI).
RESULTS
Patient characteristics
The baseline characteristics of 335 patients with MBC ob-
tained from our analysis are summarized in Table 1. The me-
dian ages at diagnosis of the primary tumor and the first me-
tastasis were 44 years (range, 22–85 years) and 47 years (range, 
26–85 years), respectively. The majority of patients had tumors 
larger than 2 cm (72.2%), and axillary metastases (70.7%). The 
percentage of patients with ER-negative and HER2-positive 
tumors was 37.3% and 14.0%, respectively. Among the pa-
tients with known tumor subtypes, 25.7% were TN. Most pa-
tients received adjuvant chemotherapy (85.9%), whereas less 
than half of the patients received adjuvant endocrine therapy 
(48.1%) or radiotherapy (41.1%). 
The median MFI was 31 months (range, 6–200 months), 
Characteristic No. (%)
Age (yr)*
   At diagnosis 44 (22–85)
   At first metastasis 47 (26–85)
Tumor size (cm)
   ≤2 93 (27.8)
   >2 242 (72.2)
Nodal status†
   Negative 94 (28.1)
   Positive 237 (70.7)
   Unknown 4 (1.2)
AJCC stage
   DCIS 2 (0.6)
   I 40 (11.9)
   II 146 (43.6)
   III 147 (43.9)
Histologic grade†
   I/II 204(60.9)
   III 99 (29.6)
   Unknown 32 (9.5)
ER and/or PR status
   Positive 194 (57.9)
   Negative 125 (37.3)
   Unknown 16 (4.8)
HER2 status‡
   Positive 47 (14.0)
   Negative 89 (26.6)
   Unknown 199 (58.4)
Ki-67†
   High (≥20%) 69 (20.6)
   Low (<20%) 22 (6.6)
   Unknown 244 (72.8)
Characteristic No. (%)
Subtype†
   HR+/HER2- 54 (16.1)
   HR+/HER2+ 19 (5.7)
   HR-/HER2+ 28 (8.4)
   TN 35 (10.4)
   Unknown 199 (59.4)
Operation type
   Mastectomy 262 (78.2)
   Breast-conserving surgery 73 (21.8)
Adjuvant chemotherapy 
   Yes 288 (85.9)
   No 47 (14.1)
Adjuvant endocrine therapy 
   Yes 161 (48.1)
   No 174 (51.9)
Adjuvant radiotherapy 
   Yes 138 (41.1)
   No 197 (58.9)
Metastasis-free interval (mo)* 31 (6–200)
   Short 133 (40.0)
   Intermediate 135 (40.0)
   Long 67 (20.0)
Site of first distant relapse†
   Bone 80 (23.9)
   Liver 65 (19.4)
   Lung 24 (7.1)
   Brain 15 (4.5)
   CNS 23 (6.9)
   Multiple 108 (32.2)
   Unknown 20 (6.0)
AJCC=American Joint Committee on Cancer; DCIS=ductal carcinoma in situ; ER=estrogen receptor; PR=progesterone receptor; HER2=human epidermal 
growth factor receptor 2; HR=hormone receptor; TN=triple-negative; CNS=central nervous system.
*Median (range); †Data with missing values; ‡HER2 positivity was defined by a 3+ score on immunohistochemistry or amplification on fluorescence in situ hybridiza-
tion.
Table 1. Baseline characteristics (n = 335) 
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where 133 patients (40.0%) had a short, and 135 patients (40.0%) 
had intermediate MFIs. A minority of patients (20.0%) devel-
oped metastases 5 years after the initial operation. At the time 
of the first distant relapse, metastasis was usually confined to a 
single organ (65.7%), most frequently the bone (23.9%).
Relationships between MFI and clinicopathologic 
characteristics
The relationships between MFI and clinicopathologic char-
acteristics are summarized in Table 2. Initially, we compared 
age at metastasis with MFI. More than half of patients aged 
less than 50 years at first distant relapse had a short MFI, while 
significantly fewer patients in the long MFI group were aged 
less than 50 years (p< 0.001). Patients with a long MFI were 
more likely to have bone metastasis, while those with a short 
MFI more frequently had central nervous system or lung me-
tastasis (data not shown). When metastatic sites were only 
classified as bone, viscera, or both, patients with a long MFI 
were still more likely to show bone metastasis, while patients 
with a short MFI were more likely to have more visceral me-
tastasis. 
Investigation into the relationship between MFI and the tu-
mor subtype revealed that approximately 50% of patients with 
a short MFI had a TN tumor, while more than half of the pa-
tients with a long MFI had HR-positive/HER2-negative tu-
mors (p< 0.001). The mean MFI was the longest in patients 
with HR-positive/HER2-negative tumors, and shortest in 
those with TN tumors (p< 0.001) (Figure 1). Furthermore, 
patients with a short MFI more frequently had larger tumors 
(p= 0.019), nodal involvement (p= 0.005), an advanced stage 
(p< 0.001), and a higher grade (p< 0.001), although Ki-67 ex-
pression in the primary tumor did not vary according to MFI 
(p= 0.233).
Survival outcome and the prognostic value of the MFI
The median follow-up duration was 61.0 months (95% CI, 
51.7–70.3), during which 247 of the 335 patients died, giving 
a median OSM of 20.0 months (95% CI, 15.9–24.1). During 
Table 2. Relationships between metastasis-free interval and clinicopathologic characteristics
Characteristic
Short MFI (n=133) 
No. (%)
Intermediate MFI (n=135) 
No. (%)
Long MFI (n=67) 
No. (%)
p-value
Age at diagnosis of metastasis (yr) <0.001
   ≥50  43 (32.3) 57 (42.2) 41 (61.1)
   <50  90 (67.7) 78 (57.8) 26 (38.9)
Simplified metastatic location 0.018
   Bone 29 (24.1) 32 (24.8) 19 (34.5)
   Viscera 60 (50.0) 41 (31.7) 15 (27.3)
   Both 31 (25.9) 56 (43.5) 21 (38.2)
Subtypes <0.001
   HR-positive/HER2-negative 9 (16.7) 27 (50.0) 18 (64.3)
   HR-positive/HER2-positive 8 (14.8) 10 (18.5) 1 (3.6)
   HR-negative/HER2-positive 12 (22.2) 10 (18.5) 6 (21.4)
   Triple-negative 25 (46.3) 7 (13.0) 3 (10.7)
Tumor size (cm) 0.019
   ≤2 26 (19.5) 47 (34.8) 20 (29.8)
   >2 107 (80.5) 88 (65.2) 47 (70.2)
Nodal status 0.005
   Negative 26 (19.8) 40 (30.1) 28 (41.7)
   Positive 105 (81.1) 93 (69.9) 39 (58.3)
Stage <0.001
   0 0 ( 0 ( 2 (3.0)
   I 9 (6.9) 20 (14.8) 11 (16.4)
   II 49 (37.4) 59 (44.3) 37 (55.2)
   III 73 (55.7) 54 (40.9) 17 (25.4)
Histologic grade <0.001
   I/II 68 (56.2) 90 (70.9) 50 (84.7)
   III 53 (43.8) 37 (29.1) 9 (15.3)
Ki-67 0.233
   Low (<20%) 27 (67.5) 35 (83.3) 8 (80.0)
   High (≥20%) 13 (32.5) 7 (16.7) 2 (20.0)
MFI=metastasis-free interval; HR=hormone receptor; HER2=human epidermal growth factor receptor 2.
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our analysis of MFI as a continuous variable, we observed that 
the risk of death after metastasis declined sharply with an in-
creasing MFI up to approximately 2 years, continued gradual-
ly declining for MFIs between 2 and 5 years, and showed no 
significant change for MFIs longer than 5 years (Figure 2). 
OSM also differed significantly depending on the MFI catego-
ry (p< 0.001) (Figure 3). Patients with a short MFI had a very 
poor outcome (median OSM, 9.0 months; 95% CI, 5.5–12.5) 
compared to those with a long MFI (median OSM, 42.0 
months; 95% CI, 25.3–58.7).
We concluded from univariate analyses that nodal status, 
stage, and HR status, were significantly correlated with OSM 
(Table 3). When adjusted for nodal status, stage, HR status, 
and metastatic site using the Cox hazards regression model, 
MFI was significantly associated with the risk of death after 
metastasis (continuous MFI: HR, 2.39, 95% CI, 1.20–4.76; 
categorized MFI: HR of intermediate MFI 0.239, 95% CI, 
Figure 1. Comparison of the mean metastasis-free interval (MFI) 
according to tumor subtype (p< 0.001; one-way analysis of varia-
tion test).
HR = hormone receptor; HER2 = human epidermal growth factor re-
ceptor 2; TN = triple-negative.
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Figure 2. Relationship between the continuous metastasis-free in-
terval (MFI) and the risk of death after metastasis. The solid curve 
represents the continuous relationship between MFI and the risk of 
death after metastasis, based on a univariate spline Cox regression 
model with three knots. Dotted curves represent 95% confidence 
intervals. 
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Table 3. Univariate analysis for overall survival after metastasis
Factor p-value*
Age at diagnosis of metastasis (yr) 0.231
   ≤50 (n=194) vs. >50 (n=141)
T stage 0.466
   >2 cm (n=242) vs. ≤2 cm (n=93)
Nodal status† 0.003
   Positive (n=237) vs. negative (n=94)
Stage 0.001
   0 & I (n=42) vs. II (n=146) vs. III (n=147)
Histologic grades† 0.061
   1 and 2 (n=208) vs. 3 (n=99)
Hormone receptor status† <0.001
   Positive (n=194) vs. negative (n=125)
Operation type 0.181
   Mastectomy (n=262) vs. breast-conserving surgery (n=73)
Adjuvant chemotherapy 0.668
   Yes (n=288) vs. no (n=47)
Adjuvant radiotherapy 0.345
   Yes (n=197) vs. no (n=138)
Simplified metastatic site† 0.002
   Bone (n=80) vs. viscera (n=127) vs. multiple (n=108)
MFI <0.001
   Short (n=133) vs. intermediate (n=135) vs. long (n=67)
MFI=metastasis-free interval.
*By the log-rank test; †Missing values are excluded.
Figure 3. Kaplan-Meier plots for overall survival after metastasis 
according to metastasis-free interval (MFI) categories (p< 0.001; 
log-rank test).
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0.174–0.330; HR of long MFI, 0.063, 95% CI, 0.039–0.102) 
(Table 4). The Harrell c indices for the models with continu-
ous and categorized MFIs were 0.834 and 0.820, respectively. 
DISCUSSION
We concluded from survival analyses that as previously re-
ported [2,4], the MFI is a significant prognostic marker for 
survival after metastasis. We report a novel finding that con-
tinuous MFI has a prognostic value in multivariate analysis, 
and therefore can potentially be used to estimate the risk of 
death after metastasis while previous studies only reported a 
prognostic value for categorized MFI in multivariate models 
for OSM [2,4].
Our investigation into the relationship between MFI and 
tumor subtype revealed that a shorter MFI was associated 
with the TN subtype while a longer MFI was associated with 
the HR-positive/HER2-negative subtype. It was previously re-
ported that the risk of early relapse is greater for women with 
ER-negative rather than ER-positive breast cancer whereas 
late relapses are more common in those with ER-positive 
rather than ER-negative disease [10-12]. In this study, we have 
identified a relationship between the MFI and the tumor sub-
type, which in turn helps to provide a biological basis for the 
duration of MFI. 
Furthermore, we report that patients with a shorter MFI 
were more likely to be younger and had visceral organ metas-
tases at the time of diagnosis. These patients often had larger 
tumors, a higher stage, a higher grade, and nodal involvement 
at initial diagnosis. We show that shorter MFI is associated 
with risk factors at the time of diagnosis for both the primary 
tumor and its metastasis, including the metastatic site. 
On the basis of our findings concerning the prognostic val-
ue of MFI for OSM, we suggest that upon validation of MFI 
as a surrogate marker of survival after distant relapse in large 
trials, it could be incorporated into a potential novel therapeu-
tic strategy for the improvement of survival outcome. Current 
trials evaluating the effect of new therapeutic interventions 
aim to reduce events of recurrence or mortality. However, our 
findings generate a new theoretical model aiming for the pro-
longation of MFI regardless of decreasing metastatic events. 
As previously reported, we show by producing comparable 
results with a longer median OSM (28.0 months) in HR-posi-
tive patients compared to HR-negative patients (12.0 months), 
that HR status is a prognostic factor for OSM [2,4,5]. Previous 
studies also showed that HR-positive status was associated 
with a reduced risk of mortality among MBC patients. Other 
factors affecting OSM were lymph node status (when adjusted 
with continuous MFI), and location of metastasis. Although 
our MBC patients had a higher than average tumor burden 
compared to other breast cancer patients, we found that the 
nodal status of the primary tumor was a significant prognostic 
Table 4. Multivariate analysis for overall survival after metastasis using the Cox regression hazard method 
Factor
With continuous MFI With categorical MFI
Hazard ratio (95% CI) p-value Hazard ratio (95% CI) p-value
MFI
   Continuous 0.964 (0.957–0.970) <0.001 NA
MFI NA
   Short Reference
   Intermediate 0.239 (0.174–0.330) <0.001
   Long 0.063 (0.039–0.102) <0.001
Hormone receptor status 0.003 0.001
   Negative Reference Reference
   Positive 0.650 (0.490–0.863) 0.627 (0.471–0.836)
Nodal status 0.009 0.053
   Positive Reference Reference
   Negative 0.584 (0.391–0.873) 0.676 (0.455–1.005)
Stage
   III Reference Reference
   II 0.884 (0.494–1.581) 0.678 1.032 (0.579–1.837) 0.139
   0 & I 0.666 (0.389–1.140) 0.139 0.726 (0.424–1.242) 0.678
Metastatic site
   Multiple Reference Reference
   Viscera 1.071 (0.795–1.444) 0.653 1.054 (0.699–1.286) 0.734
   Bone 0.466 (0.320–0.678) <0.001 0.439 (0.300–0.641) <0.001
MFI=metastasis-free interval; CI=confidence interval; NA=not applicable.
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factor for OSM. This may be because of the contribution of 
many factors towards the overall prognoses of both primary 
breast cancer and MBC [3,15]. 
In addition to lymph node status, we also show that the lo-
cation of the metastasis is a significant predictive factor for 
OSM. The median OSM of patients with initial bone-only 
metastasis was 40 months, which was longer than that of pa-
tients with multiple metastases or visceral metastasis at initial 
distant relapse (20.0 months and 14.0 months, respectively). 
The favorable OSM in patients with initial bone-only metasta-
sis is also consistent with the findings reported in previous 
studies [15-17]. 
We acknowledge several limitations inherent to the retro-
spective design of this study. Palliative treatments were not in-
cluded in the survival analyses owing to their heterogeneity 
and information on HER2 status and subtype was missing for 
more than half of the patients. Consequently, the therapeutic 
effect of trastuzumab in the palliative or adjuvant setting was 
not accounted for in this study. In addition, the study was 
conducted on a small population of patients at a single insti-
tute that may not be representative of the general MBC pa-
tient population. Nevertheless, we found that MFI is associat-
ed with biological traits and may be helpful if used in combi-
nation with other prognostic markers. 
In conclusion, our findings show that MFI is closely related 
to tumor characteristics of both primary tumors and their 
metastases, and that it is a significant prognostic factor for 
survival after metastasis. In conclusion, we suggest using MFI 
as an easy to calculate surrogate marker of survival in clinical 
trials.
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